



JPW

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

<b>INFORMATION DISCLOSURE STATEMENT</b>		Docket Number: 1662/63303	
Application Number 10/802,627	Filing Date March 17, 2004	Examiner Susannah E. Lee	Art Unit 1626
Invention Title  POLYMORPHS OF VALSARTAN		Inventor(s) RUKHMAN, et al.	

Address to

Mail Stop: Amendments  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:  
Mail Stop: Amendments  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450  
on  
Date: Jan 30, 2006  
Signature: Regina Galan

Sir:

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. The references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue there from. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. Copies of each patent, publication or other information listed on the modified PTO Form No. 1449 are enclosed, except as otherwise specified.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge deposit account number 11-0600 for such fees. A duplicate of this communication is enclosed for charging purposes.

Dated: Jan 30, 06

By:

Payam Moradian  
Payam Moradian (Reg. No. 52048)  
KENYON & KENYON LLP  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)  
CUSTOMER NO. 26646



<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449</b>	ATTY. DOCKET NO. 1662/63303	SERIAL NO. 10/802,627
	APPLICANT RUKHMAN et al.	
	FILING DATE March 17, 2004	GROUP 1626

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0443983 B1	February 12, 1991	EPO				
	00570091 A1	February 24, 1993	EPO				
	WO 01/82858 A2	November 8, 2001	PCT				
	WO 01/82858 A3	November 8, 2001	PCT				
	WO 02/06253 A1	January 24, 2002	PCT				
	WO 03/070246 A1	August 28, 2003	PCT				
	WO 03/089417 A1	October 30, 2003	PCT				
	WO 2004/026847 A1	April 1, 2004	PCT				
	WO 2004/094392 A1	November 4, 2004	PCT				
	WO 97/30036	August 21, 1997	PCT				
	WO 99/01459	January 14, 1999	PCT				
	WO 99/67231	December 29, 1999	PCT				
	WO 2005/089720 A1	September 29 2005	PCT				

**OTHER DOCUMENTS**

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Buhlmayer, Peter, et al., Valsartan, A Potent, Orally Active Angiotensin II Antagonist Developed From The Structurally New Amino Acid Series, Bioorganic & Medical Chemistry Letters, 1994, Vol. 4, No. 1, pp. 29-34.
	Borka, Laszlo, Crystal Polymorphism of Pharmaceuticals, Acta Pharmaceutica Jugoslavica, 1990, pp. 71-94.
	Moenius, Th., et al., Carbon-14 Labelling of Diovan™ in its Valine-Moiety, Journal of Labelled Compounds and Radiopharmaceuticals, 2000, Vol. 43, pp. 1245-1252.
	Zhong Guo, et al. Chinese Journal of Pharmaceuticals, 2002, Vol. 32 Part 9, pp. 385-387.
	The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, 1996, pp. 1691.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	